Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study

Arthritis and Rheumatism

Volumn 43, Issue 9, 2000, Pages 2025-2033

  Boomsma, M M ^a   Stegeman, C A ^a   Van Der Leij, M J ^a   Oost, W ^a   Hermans, J ^b   Kallenberg, C G M ^a   Limburg, P C ^a   Cohen Tervaert, J W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; RISK ASSESSMENT; WEGENER GRANULOMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIBODY SPECIFICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PEROXIDASE; RECURRENCE; ROC CURVE; WEGENER GRANULOMATOSIS;

EID: 0033711858     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O     Document Type: Article

References (32)

1. Wegener's granulomatosis: Pathology and review of the literature
2. Wegener granulomatosis: An analysis of 158 patients
3. Damage occurs early in systemic vasculitis and is an index of outcome
4. Association between active Wegener's granulomatosis and anticytoplasmic antibodies
5. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre
6. Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides
7. Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: A longitudinal study comparing anti-endothelial cell antibodies and anti-neutrophil cytoplasm antibodies
8. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis
9. Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test
10. Serial ANCA testing is useful in monitoring disease activity in patients with ANCA associated vasculitides
11. Serial ANCA testing has limited value during the follow-up of disease activity in patients with ANCA-associated vasculitis
12. Rise in ANCA titer: To treat or not to treat
13. The value of indirect immunofluorescence and solid phase techniques for ANCA detection: A report on the first phase of an international cooperative study on the standardization of ANCA assays
14. Measurement of IgG3 of anti-proteinase 3 antibodies to neutrophil cytoplasm is useful in monitoring disease activity in Wegener's granulomatosis
15. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis
16. Nomenclature of systemic vasculitides: Proposal of an international consensus conference
17. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis
18. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis
19. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group
20. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis
21. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis
22. World Medical Association Declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects
23. Occurrence of autoantibodies to human leucocyte elastase in Wegener's granulomatosis and other inflammatory disorders
24. Cleavage and inactivation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3
25. Antimyeloperoxidase-associated proliferative glomerulonephritis: An animal model
26. Differential B- and T-cell activation in Wegener's granulomatosis
27. ANCA and predicting relapse in systemic vasculitis
28. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis
29. A proportion of proteinase 3 (PR3)-specific anti-neutrophil cytoplasmic antibodies (ANCA) only react with PR3 after cleavage of its N-terminal activation dipeptide
30. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis
31. Pathophysiology of ANCA-associated glomerulonephritis